Aurélie Karch-Georges1, Francis Veillon1, Hella Vuong2, Dominique Rohmer2, Anne Karol1, Anne Charpiot2, Nicolas Meyer3, Aina Venkatasamy4,5. 1. Service de Radiologie 1, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098, Strasbourg CEDEX, France. 2. Service de chirurgie ORL, Hôpitaux Universitaires de Strasbourg, 1 avenue Molière, 67098, Strasbourg CEDEX, France. 3. Département de Statistiques, Hôpitaux Universitaires de Strasbourg, 1 place de L'hôpital, 67000, Strasbourg, France. 4. Service de Radiologie 1, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098, Strasbourg CEDEX, France. aina.venkatasamy@chru-strasbourg.fr. 5. Laboratory Stress Response and Innovative Therapies "Streinth", Université de Strasbourg, Inserm IRFAC UMR_S1113, Strasbourg, France. aina.venkatasamy@chru-strasbourg.fr.
Abstract
OBJECTIVE: Vestibular schwannomas (VS) may present with similar symptoms endolymphatic hydrops. Association between hydrops and internal auditory canal VS has been described by Naganawa et al. (Neuroradiology 53:1009-1015, 2011), but has never been confirmed since. The aim of this work was to study the prevalence of a saccular dilation on a T2-weighted sequence at 3 T MRI in VS compared to a control group. MATERIALS AND METHODS: All patients presenting with typical VS between May 2009 and July 2018 were included (n = 183) and compared to a control group (n = 53). All underwent a high-resolution T2-weighted 3D sequence (FIESTA-C). The height and width of the saccule were measured on a coronal plane by two radiologists. RESULTS: The saccule was dilated on the side of the schwannoma in 28% of the cases (p = 2.81 × 10- 5), with 15.7% of bilateral dilation. Saccular dilation was correlated to sensorineural hearing loss (OR 3.26, p = 0.02). There was also a significant correlation between saccular hydrops on the normal contralateral side of patients with VS and vertigo (p = 0.049), and between saccular hydrops on the side of the tumour and tinnitus (p = 0.006). CONCLUSION: A third (29%) of VS are associated with a saccular dilation on the side of the tumour, which is an MR sign of endolymphatic hydrops (bilateral in 15.7% of the cases) and it appears related to sensorineural hearing loss and tinnitus, as well as vertigo if a contralateral dilation is present. This opens new therapeutic potentialities with the use of anti-vertiginous drugs, which could have a beneficial effect on the clinical symptoms.
OBJECTIVE:Vestibular schwannomas (VS) may present with similar symptoms endolymphatic hydrops. Association between hydrops and internal auditory canal VS has been described by Naganawa et al. (Neuroradiology 53:1009-1015, 2011), but has never been confirmed since. The aim of this work was to study the prevalence of a saccular dilation on a T2-weighted sequence at 3 T MRI in VS compared to a control group. MATERIALS AND METHODS: All patients presenting with typical VS between May 2009 and July 2018 were included (n = 183) and compared to a control group (n = 53). All underwent a high-resolution T2-weighted 3D sequence (FIESTA-C). The height and width of the saccule were measured on a coronal plane by two radiologists. RESULTS: The saccule was dilated on the side of the schwannoma in 28% of the cases (p = 2.81 × 10- 5), with 15.7% of bilateral dilation. Saccular dilation was correlated to sensorineural hearing loss (OR 3.26, p = 0.02). There was also a significant correlation between saccular hydrops on the normal contralateral side of patients with VS and vertigo (p = 0.049), and between saccular hydrops on the side of the tumour and tinnitus (p = 0.006). CONCLUSION: A third (29%) of VS are associated with a saccular dilation on the side of the tumour, which is an MR sign of endolymphatic hydrops (bilateral in 15.7% of the cases) and it appears related to sensorineural hearing loss and tinnitus, as well as vertigo if a contralateral dilation is present. This opens new therapeutic potentialities with the use of anti-vertiginous drugs, which could have a beneficial effect on the clinical symptoms.
Authors: D Y Kim; J H Lee; M J Goh; Y S Sung; Y J Choi; R G Yoon; S H Cho; J H Ahn; H J Park; J H Baek Journal: AJNR Am J Neuroradiol Date: 2014-04-17 Impact factor: 3.825
Authors: Luis Lassaletta; Miryam Calvino; Jose Manuel Morales-Puebla; Pablo Lapunzina; Lourdes Rodriguez-de la Rosa; Isabel Varela-Nieto; Victor Martinez-Glez Journal: Front Neurol Date: 2019-09-18 Impact factor: 4.003
Authors: Marly F J A van der Lubbe; Akshayaa Vaidyanathan; Vincent Van Rompaey; Alida A Postma; Tjasse D Bruintjes; Dorien M Kimenai; Philippe Lambin; Marc van Hoof; Raymond van de Berg Journal: J Neurol Date: 2020-11-17 Impact factor: 4.849